[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cord-blood\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cord-blood":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,58,92,116],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":40,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":47,"lastUpdatePostDateStruct":48,"startDateStruct":51,"completionDateStruct":52,"leadSponsor":54,"locationsCount":57},"100614048","amnioinfusions-protective-effects-on-respiratory-and-longitudinal-pediatric-outcomes-after-intrapartum-thick-meconium-exposure-100614048",false,"NCT07274527","Amnioinfusion's Protective Effects on Respiratory and Longitudinal Pediatric Outcomes After Intrapartum Thick Meconium Exposure","The PEARL Trial: A Randomized Trial of Amnioinfusion's Protective Effects on Respiratory and Longitudinal Pediatric Outcomes After Intrapartum Thick Meconium Exposure","PEARL","Inclusion Criteria:\n\n* Maternal age greater than or equal to 18 years old\n* Singleton pregnancy\n* Gestational age of greater than or equal to 36 weeks 0 days gestation\n* Cephalic presentation\n* Cercial dilation between 2-10 centimeters\n* Meconium\n\nExclusion Criteria:\n\n* Major fetal anomaly\n* Multiple gestation\n* Eunice Kennedy Shrive National Institute of Child Health and Human Developmet (NICHD) Category III fetal heart tracing\n* Contraindication to internal monitors\n* Prelabor premature ruptuore of membranes before 36 weeks 0 days gestation, - Inability to consent","ALL","18 Years",{"count":20,"type":21},320,"ESTIMATED","INTERVENTIONAL",[24],"NA","Thick meconium in the amniotic fluid occurs in about one out of seven pregnancies and increases the chance that a newborn may have breathing problems after birth. These problems can include the need for oxygen, breathing support, admission to the neonatal intensive care unit (NICU), or, in severe cases, meconium aspiration syndrome or persistent pulmonary hypertension.\n\nAlthough amnioinfusion or placing sterile fluid into the uterus during labor was previously studied as a way to reduce these complications, earlier research had major limitations. Past studies included all types of meconium, used different fluid types and temperatures, had inconsistent protocols, and did not measure biomarkers of inflammation or look at long-term outcomes. As a result, it is still unclear whether a modern, standardized approach to amnioinfusion can meaningfully improve newborn health when the meconium is truly thick.\n\nThe PEARL Trial is a randomized clinical trial designed to answer this question. The study will enroll pregnant individuals at or beyond 36 weeks of gestation who develop thick meconium-stained amniotic fluid, confirmed using a simple, objective measurement (\"meconium-crit\"). Participants will be randomly assigned to receive either:\n\nWarm lactated Ringer's (LR) amnioinfusion through an intrauterine pressure catheter (IUPC), following a standardized protocol, or standard care without amnioinfusion.\n\nThe main goal is to determine whether warm LR amnioinfusion reduces short-term breathing problems in newborns. The study also collects umbilical cord blood at birth to evaluate markers of inflammation and potential brain injury, which may help explain why some infants develop complications. Families will also be contacted when their child is 12 months old to complete a developmental questionnaire that is widely used in pediatric practice.\n\nBy using a clear definition of thick meconium, a warm LR infusion protocol, fidelity checklists, and long-term follow-up, this trial aims to provide high-quality evidence to guide care in labor and delivery units nationwide.",[27,28,29,30,31,32,33,34,35,36,37,38,39],"Neonatal Respiratory Distress Related Conditions","Meconium","Perinatal Morbidity","Neonatal Acidosis","Cord Blood","Neonatal Brain Injury","Maternal Morbidity","Mechanical Ventilation","CPAP","Surfactant","Perinatal Death","Amnioinfusion","NICU Admission",[38,28,41,42,33,43,44,45],"Neonatal morbidity","Developmental Screening","Neonatal respiratory morbidity","Umbilical cord gas and biomarkers","Healthcare Utilization","RECRUITING","2026-05-15",{"date":49,"type":50},"2026-05-19","ACTUAL",{"date":47,"type":50},{"date":53,"type":21},"2030-04-15",{"name":55,"class":56},"Medical College of Wisconsin","OTHER",1,{"id":59,"slug":60,"hasResults":11,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":64,"eligibilityCriteria":65,"healthyVolunteers":11,"sex":66,"minAge":18,"maxAge":67,"enrollmentInfo":68,"targetDuration":4,"studyType":22,"phases":70,"briefSummary":71,"conditions":72,"keywords":78,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":57},"100593781","platelet-rich-plasma-injections-from-cord-blood--penile-traction-vs-penile-traction-alone-in-patients-with-peyronies-disease-open-label-single-center-randomized-study-100593781","NCT07010900","Platelet-Rich Plasma Injections From Cord Blood + Penile Traction vs. Penile Traction Alone in Patients With Peyronie's Disease. Open-label, Single-center Randomized Study","Platelet-Rich Plasma Injections From Cord Blood + Penile Traction vs. Penile Traction Alone in Patients With Peyronie's Disease.","CB-PRP-TRAC1","Inclusion Criteria:\n\n* Patients with Peyronie's Disease (IPP) Penile curvature greater than 30 degrees (autophotography in erection with goniometer measurement) Patients candidates for penile traction Age: 18-75 years Good health conditions Preserved erection (IIEF \\>20) Complete blood count with differential and coagulation within the normal range (platelets between 150,000 and 450,000 μL) HIV, HCV, and HbsAg negative The fertile partner of the patient randomized to the experimental group must use an acceptable highly effective contraceptive method (oral contraceptives, intrauterine device, abstinence, vasectomized partner) for the entire duration of the study Informed consent to the study\n\nExclusion Criteria:\n\nCoagulopathies, platelet disorders Major active infections Previous penile surgery (excluding circumcision and condyloma removal) Previous infiltrative therapy or penile traction treatment","MALE","75 Years",{"count":69,"type":21},42,[24],"The goal of this clinical trial is to learn if Platelet-Rich Plasma Injections from Cord Blood (CB-PRP) is useful in Peyronie disease.\n\nThe primary goal is evaluation of patient satisfaction at 1 and 3 months after treatment completion using the PDQ Questionnaire\n\nSecondary Objectives are:\n\n* Measurement of penile curvature measured with a goniometer with spontaneous erection before and after treatment (1 and 3 months)\n* Measurement of penile length in stretching before and after treatment (1 and 3 months)\n* Evaluation of the improvement in quality of life, through the Short-Form Health Survey 12 (SF-12) health status questionnaire and through the Hospital Anxiety and Depression Scale (HADS)\n\nParticipants will be randomized in two groups:\n\n* penile extender alone\n* penile extender + CB PRP injection (1 injection every 15 days - 3 in totalinjections)",[73,74,75,31,76,77],"Peyronie Disease","Penile Curvature","PRP Injection","Randomised Clinical Trial","Penile Injection Therapy",[79,80,81,82],"penile exteder","peyronie disease","prp","cord blood prp","2025-05-30",{"date":85,"type":50},"2025-06-08",{"date":87,"type":21},"2025-05-28",{"date":89,"type":21},"2026-12-31",{"name":91,"class":56},"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico",{"id":93,"slug":94,"hasResults":11,"nctId":95,"briefTitle":96,"officialTitle":97,"acronym":4,"eligibilityCriteria":98,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":99,"targetDuration":4,"studyType":22,"phases":101,"briefSummary":103,"conditions":104,"keywords":4,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":57},"100545431","phase-3-haplo-cord-hct-vs-haplo-hct-for-t-all-patients-100545431","NCT06381817","Haplo-cord HCT vs. Haplo-HCT for T-ALL Patients","Haploidentical Hematopoietic Cell Transplantation Combined With an Unrelated Cord Blood Unit for Acute T Cell Lymphoblastic Leukemia Compared to Haploidentical Hematopoietic Cell Transplantation: a Multicenter, Randomized, Open-label Trial","Inclusion Criteria:\n\n* Patients with acute T cell lymphoblastic leukemia\n* With available minimal residual disease parameters assessed by flow cytometry and\u002For quantitative polymerase chain reaction\n* Willing to undergo haploidentical hematopoietic cell transplantation and having a suitable haploidentical donor\n* With Eastern Cooperative Oncology Group (ECOG) performance status of 0-3\n* Signing an informed consent form, having the ability to comply with study and follow-up procedures\n\nExclusion Criteria:\n\n* With other malignancies\n* Failing to acquire a suitable unrelated cord blood unit\n* With a previous history of autologous hematopoietic cell transplantation, allogeneic hematopoietic cell transplantation or chimeric antigen receptor T cell therapy\n* With uncontrolled infection intolerant to haploidentical hematopoietic cell transplantation\n* With severe organ dysfunction\n* In pregnancy or lactation period\n* With any conditions not suitable for the trial (investigators' decision)",{"count":100,"type":21},146,[102],"PHASE3","The goal of this clinical trial is to learn if haploidentical hematopoietic cell transplantation combined with an unrelated cord blood unit (haplo-cord HCT) works to treat acute T cell lymphoblastic leukemia (T-ALL). It will also learn about the safety of the transplantation. The main questions it aims to answer are:\n\nDose co-infusion of cord blood in haploidentical hematopoietic cell transplantation (haplo-HCT) lower the rate of relapse? What medical problems do participants have when having haplo-cord HCT? Researchers will compare haplo-cord HCT to haplo-HCT to see if haplo-cord HCT works to treat T-ALL.\n\nParticipants will be infused an unrelated cord blood unit at the same day of haploidentical graft infusion.",[105,106,31],"Acute T Cell Lymphoblastic Leukemia","Haploidentical Hematopoietic Stem Cell Transplantation","2024-04-24",{"date":109,"type":50},"2024-04-26",{"date":111,"type":50},"2024-04-01",{"date":113,"type":21},"2028-03-31",{"name":115,"class":56},"The First Affiliated Hospital of Soochow University",{"id":117,"slug":118,"hasResults":11,"nctId":119,"briefTitle":120,"officialTitle":121,"acronym":4,"eligibilityCriteria":122,"healthyVolunteers":11,"sex":17,"minAge":123,"maxAge":18,"enrollmentInfo":124,"targetDuration":4,"studyType":22,"phases":126,"briefSummary":127,"conditions":128,"keywords":4,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":57},"100528009","post-transplant-ptflucy-promotes-unrelated-cord-blood-engraftment-in-haplo-cord-setting-in-childhood-leukemia-100528009","NCT06155188","Post-transplant PT\u002FFLU+CY Promotes Unrelated Cord Blood Engraftment in Haplo-cord Setting in Childhood Leukemia","A Novel Post-transplant Regimen of PT\u002FFLU+CY for Selectively Promoting Unrelated Cord Blood Engraftment in Haploidentical-cord Transplantation in Childhood Leukemia: a Single-arm, Multi-center Trial","Inclusion Criteria:\n\n* children acute leukemia\n\nExclusion Criteria:\n\n* MODS","1 Month",{"count":125,"type":21},60,[24],"To determine if the novel regimen of PT\u002FFLU+CY promotes cord blood engraftment in children's leukemia HSCT cohort",[129,130,31],"Leukemia","Stem Cell Transplant","2023-11-23",{"date":133,"type":50},"2023-12-04",{"date":135,"type":50},"2019-09-29",{"date":137,"type":21},"2026-12",{"name":139,"class":56},"Nanfang Hospital, Southern Medical University"]